Archives
What a Targeted Rabbit Pharming Line Shows
2026-11-05
A 2025 study tested whether placing a reporter gene under endogenous β-casein regulatory control could raise recombinant-protein accumulation in rabbit milk. The reported 15–20 g/L result is substantial, but its interpretation is bounded by the small number of producing animals, the use of a reporter rather than a therapeutic protein, and the absence of a direct matched comparison.
What a High-Yield Rabbit Pharming Study Shows
2026-11-05
A targeted insertion at the endogenous CSN2 locus produced 15–20 g/L tdTomato in milk from two homozygous rabbits, but the result remains a feasibility signal rather than a validated platform for therapeutic proteins.
When Experimental Context Changes a Yield Result
2026-11-04
A reported concentration becomes scientifically meaningful only when its biological model, genetic context, comparator, and measurement endpoint are clear. The rabbit pharming study illustrates why a high reporter concentration can support a strong proof of concept while remaining insufficient to establish therapeutic-product performance or general manufacturing applicability.
Condensate Coronas and Intracellular RNA Access
2026-11-04
A nanoparticle can acquire a cell-derived condensate corona that changes its extracellular identity, endosomal behavior and capacity to transfer proteins and RNAs. The evidence supports a rare-event mechanism involving selective re-export, endosomal detachment and cytosolic access, while leaving transfer frequency, generality and molecular recognition partners incompletely defined.
How CMC Shapes mRNA-LNP Translation
2026-11-03
A literature-focused analysis of how lipid chemistry, manufacturing strategy, analytical control and comparability planning shape the translation of mRNA lipid nanoparticles from research platforms into clinically credible products.
CSN2 Targeting and Rabbit Pharming Yield
2026-11-03
A literature-focused analysis of how endogenous CSN2 regulation, targeted integration, and germline transmission shaped the reported high-yield rabbit line—and why the result should not yet be generalized to therapeutic proteins.
SCP4, H3T3 Phosphorylation, and Mitotic Fidelity
2026-11-02
A mechanistic study identifies SCP4 as a phosphatase that counterbalances Haspin-dependent H3T3 phosphorylation and links this activity to chromosomal passenger complex localization, chromosome segregation, and early embryonic mitosis. The evidence also clarifies why 2-Thio-dCTP belongs to a distinct DNA-centered measurement context rather than serving as evidence for histone phosphatase activity.
Laurdan Readouts in Dynamic Lipid Nanoparticles
2026-11-02
Laurdan generalized polarization can report membrane hydration and lipid packing, but it is not a direct measure of PEG cleavage, nanoparticle uptake, mRNA expression, or therapeutic efficacy. The cited study supports kinetic control of PEG shedding as a route-dependent delivery principle; Laurdan is most informative as complementary physical-state evidence.
What mRNA-LNP Translation Evidence Really Shows
2026-11-01
A claim-focused synthesis of how lipid chemistry, critical quality attributes, manufacturing comparability, and physiological stability shape the translation of mRNA lipid nanoparticles.
A Precise Promoter Strategy for Rabbit Pharming
2026-10-31
A 2025 study tested whether placing a reporter gene at the rabbit CSN2 locus could leverage endogenous milk-protein regulation to increase recombinant protein output. The reported 15–20 g/L milk concentration is striking, but its interpretation is bounded by the small number of animals, the use of tdTomato rather than a therapeutic protein, and the absence of a direct matched comparison with conventional lines.
How LNP Chemistry Shapes mRNA Translation
2026-10-30
mRNA–lipid nanoparticles succeed when lipid chemistry, particle attributes, physiological behavior, and manufacturing controls are interpreted as one causal system. A recent review clarifies which measurements support mechanistic claims—and which remain only indirect proxies for cellular delivery or clinical performance.
Why CSN2 Knock-In Raises Rabbit Milk Output
2026-10-30
A 2025 study links targeted insertion at the rabbit CSN2 milk-protein locus with recombinant tdTomato concentrations of 15–20 g/L in milk from homozygous animals. The finding supports a strong locus-and-promoter effect, but concentration data from a reporter protein and a small number of animals do not yet establish equivalent performance for therapeutic proteins or industrial-scale output.
Why a Milk-Protein Locus Raised Rabbit Pharming Yield
2026-10-29
A 2025 study linked targeted insertion at the rabbit CSN2 locus with recombinant-protein concentrations of 15–20 g/L in milk from two homozygous animals. The result supports a locus-and-promoter mechanism, but it remains a small, surrogate-protein demonstration rather than a general validation of therapeutic manufacturing.
When Context Changes a Protein-Yield Result
2026-10-29
A reported 15–20 g/L recombinant-protein concentration in rabbit milk is meaningful only when its promoter, genotype, protein identity, comparator, and measurement scale are kept in view. The study illustrates how genetic context can change both the biological interpretation and the strength of a production claim.
How to Interpret trans-Cinnamic Acid Signals
2026-10-28
A molecular-interpretation framework for separating what trans-cinnamic acid’s structure can explain from what a biological or analytical readout would still need to demonstrate.